Unverified50% confidenceDecision RuleExact time
The study argues that the clinical value of synthetic data should be judged comprehensively through calibration, decision curve analysis, and clinician review, rather than relying solely on discriminative performance (such as AUROC).
1
Sources
50%
Confidence
Long-term
Relevance
11/10/2026
First Seen
Sources
Related Entities
Related Claims
UnverifiedDuring development, synthetic samples should be used instead of real patient data to validate the tools, and both successful and uncertain results should be checked, comparing reported counts against the generated audit rows.77% similarUnverifiedThe study recommends that evaluating medical models should not rely solely on knowledge-based benchmarks but should also incorporate clinical reasoning assessments.77% similarUnverified医学AI临床验证的性能基准须针对目标人群建立,不能直接沿用公开数据集的评测结果,需通过多中心前瞻性研究证明安全性和有效性77% similarUnverifiedThe medical community generally holds that screening should target people with clear risk factors or symptoms, rather than being applied indiscriminately for "optimization" purposes.74% similarUnverifiedThe authors position the contribution of this study as methodological robustness under fragmented assessment, rather than providing a clinical drug resistance ranking.74% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1153547API
curl https://kongchang.com/api/v1/knowledge/claims/1153547MCP
get_claim(id=1153547)